Hyderabad News Desk

Chronic Lower Back Pain Market

(Albany, USA) DelveInsight’s “Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Lower Back Pain, historical and forecasted epidemiology as well as the Chronic Lower Back Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Lower Back Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Lower Back Pain Market Forecast

Some of the key facts of the Chronic Lower Back Pain Market Report: 

• The Chronic Lower Back Pain market size was valued approximately USD 6,227 Million in 2020 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In the 7MM, there were a total of 77,300,000 prevalent cases of CLBP in 2022. It is anticipated that there would be an increase in CLBP patients in the 7MM from 2019 to 2032
• Spain had the highest prevalence of CLBP cases in the EU4 with 8,930,000 cases, followed by the UK with 6,040,000 cases in 2022
• In 2022, there were 12,700,000 cases of Chronic Lower Back Pain in Japan.
• In February 2023, Camurus withdrew the CAM2038 application once it was expanded to cover chronic pain.
• In February 2023, Rexlemestrocel-L was given the RMAT designation by the FDA for regenerative medicine advanced therapy (chronic lower back pain).
• Key Chronic Lower Back Pain Companies: Eli Lilly and Company, Camurus/Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc, Pfizer, Endo Pharmaceuticals, Persica Pharmaceuticals, Collegium Pharma, DOV Pharma, Mallinckrodt, Grünenthal GmbH, AbbVie, and others
• Key Chronic Lower Back Pain Therapies: LY3016859, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Semdexa (SP-102), Rexlemestrocel-L (MPC-06-ID), AMG0103, Duloxetine, buprenorphine, Celebrex 200mg, Oxymorphone ER, PP353, Oxycodone DETERx, Bicifadine, OROS hydromorphone, EN3324 (axomadol), ABT-712, and others
• The Chronic Lower Back Pain epidemiology based on gender analyzed that most of the CLBP cases include female population as compared to male patient pool
• The Chronic Lower Back Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Lower Back Pain pipeline products will significantly revolutionize the Chronic Lower Back Pain market dynamics.

Chronic Lower Back Pain Overview

Acute low back pain can be caused by an injury or other underlying condition, but chronic low back pain (CLBP) lasts for 12 weeks or more. Everyone has had low back pain at some point because it is so prevalent.

Get a Free sample for the Chronic Lower Back Pain Market Report – https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market

Chronic Lower Back Pain Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Lower Back Pain Epidemiology Segmentation:

The Chronic Lower Back Pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Chronic Lower Back Pain
• Prevalent Cases of Chronic Lower Back Pain by severity
• Gender-specific Prevalence of Chronic Lower Back Pain
• Diagnosed Cases of Episodic and Chronic Chronic Lower Back Pain

Download the report to understand which factors are driving Chronic Lower Back Pain epidemiology trends @ Chronic Lower Back Pain Epidemiology Forecast

Chronic Lower Back Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Lower Back Pain market or expected to get launched during the study period. The analysis covers Chronic Lower Back Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Lower Back Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Lower Back Pain Therapies and Key Companies

• LY3016859: Eli Lilly and Company
• Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.
• Semdexa (SP-102): Scilex Holding
• Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited
• AMG0103: AnGes MG, Inc
• Duloxetine: Eli Lilly and Company
• buprenorphine: Braeburn Pharmaceuticals
• Celebrex 200mg: Pfizer
• Oxymorphone ER: Endo Pharmaceuticals
• PP353: Persica Pharmaceuticals
• Oxycodone DETERx: Collegium Pharma
• Bicifadine: DOV Pharma
• OROS hydromorphone: Mallinckrodt
• EN3324 (axomadol): Grünenthal GmbH
• ABT-712: AbbVie

Discover more about therapies set to grab major Chronic Lower Back Pain market share @ Chronic Lower Back Pain Treatment Market

Scope of the Chronic Lower Back Pain Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Lower Back Pain Companies: Eli Lilly and Company, Camurus/Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc, Pfizer, Endo Pharmaceuticals, Persica Pharmaceuticals, Collegium Pharma, DOV Pharma, Mallinckrodt, Grünenthal GmbH, AbbVie, and others
• Key Chronic Lower Back Pain Therapies: LY3016859, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Semdexa (SP-102), Rexlemestrocel-L (MPC-06-ID), AMG0103, Duloxetine, buprenorphine, Celebrex 200mg, Oxymorphone ER, PP353, Oxycodone DETERx, Bicifadine, OROS hydromorphone, EN3324 (axomadol), ABT-712, and others
• Chronic Lower Back Pain Therapeutic Assessment: Chronic Lower Back Pain current marketed and Chronic Lower Back Pain emerging therapies
• Chronic Lower Back Pain Market Dynamics: Chronic Lower Back Pain market drivers and Chronic Lower Back Pain market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Chronic Lower Back Pain Unmet Needs, KOL’s views, Analyst’s views, Chronic Lower Back Pain Market Access and Reimbursement 

To know more about Chronic Lower Back Pain companies working in the treatment market, visit @ Chronic Lower Back Pain Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Chronic Lower Back Pain Market Report Introduction

2. Executive Summary for Chronic Lower Back Pain

3. SWOT analysis of Chronic Lower Back Pain

4. Chronic Lower Back Pain Patient Share (%) Overview at a Glance

5. Chronic Lower Back Pain Market Overview at a Glance

6. Chronic Lower Back Pain Disease Background and Overview

7. Chronic Lower Back Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Lower Back Pain 

9. Chronic Lower Back Pain Current Treatment and Medical Practices

10. Chronic Lower Back Pain Unmet Needs

11. Chronic Lower Back Pain Emerging Therapies

12. Chronic Lower Back Pain Market Outlook

13. Country-Wise Chronic Lower Back Pain Market Analysis (2019–2032)

14. Chronic Lower Back Pain Market Access and Reimbursement of Therapies

15. Chronic Lower Back Pain Market Drivers

16. Chronic Lower Back Pain Market Barriers

17.  Chronic Lower Back Pain Appendix

18. Chronic Lower Back Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services